Structural Biology Core Facility The Structural Biology Core is a 'super core'that provides an integrated platform of expertise, education, and infrastructure to make structural biology available as tools to LCCC researchers. The Core allows engaging in high-resolution studies using X-ray crystallography, multi-dimensional nuclear magnetic resonance spectroscopy and/or computational methods. The Core offers access to equipment for, and expert guidance of users through, all stages of structure determination projects: homology modeling, construct design, protein expression &purification, crystallization, structure determination, structure analysis, biophysical studies, molecular dynamics studies, presentation &publication. The utility of the available resources is demonstrated by numerous structural studies that contribute to the understanding of cancer-related processes at the atomic level and that can be used to develop potential new therapies through structure aided drug design. The Core is led by a team of highly experienced structural biologists with proven track records in cancer-related research In 2009, 32 LCCC members, all peer-reviewed accounted for 82% of total Core use.. With the recruitment of a director for the Core, Dr. Machius, in the summer of 2009, there has been a reorganization of the facilities, together with substantial renovations and equipment acquisition. As a result of the expanded services and increased demand, the number of projects is increasing sharply. Additional personnel are required to fulfill the needs of LCCC members. Renovations are currently underway to consolidate the Structural Biology facilities into contiguous space, providing a single point of access to resources and allowing for fighter integration of equipment and personnel. Also, an efficient interface is being formed between the Structural Biology Core and the Center for Integrative Chemical Biology and Drug Discovery (directed by Dr. Stephen Frye), which will establish a comprehensive pipeline available to LCCC members for the development of novel anti-cancer drugs based on insights gained from structural biology projects. For 2010, the LCCC requests $119,367, an increase of 29% for additional personnel). CCSG funds are projected to be 15% of operating costs.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of North Carolina Chapel Hill
Chapel Hill
United States
Zip Code
Joseph, Sarah B; Arrildt, Kathryn T; Sturdevant, Christa B et al. (2015) HIV-1 target cells in the CNS. J Neurovirol 21:276-89
Sikov, William M; Berry, Donald A; Perou, Charles M et al. (2015) Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (A J Clin Oncol 33:13-21
Blazer, Marlo; Wu, Christina; Goldberg, Richard M et al. (2015) Neoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderline resectable (BRPC) adenocarcinoma of the pancreas. Ann Surg Oncol 22:1153-9
Knight, E R W; Patel, E Y; Flowers, C A et al. (2015) ASC deficiency suppresses proliferation and prevents medulloblastoma incidence. Oncogene 34:394-402
Dellon, Evan S; Speck, Olga; Woodward, Kimberly et al. (2015) Distribution and variability of esophageal eosinophilia in patients undergoing upper endoscopy. Mod Pathol 28:383-90
Qi, Qibin; Kilpeläinen, Tuomas O; Downer, Mary K et al. (2014) FTO genetic variants, dietary intake and body mass index: insights from 177,330 individuals. Hum Mol Genet 23:6961-72
Jha, Deepak Kumar; Strahl, Brian D (2014) An RNA polymerase II-coupled function for histone H3K36 methylation in checkpoint activation and DSB repair. Nat Commun 5:3965
Guo, Shutao; Lin, C Michael; Xu, Zhenghong et al. (2014) Co-delivery of cisplatin and rapamycin for enhanced anticancer therapy through synergistic effects and microenvironment modulation. ACS Nano 8:4996-5009
Clark, Martha A; Goheen, Morgan M; Spidale, Nicholas A et al. (2014) RBC barcoding allows for the study of erythrocyte population dynamics and P. falciparum merozoite invasion. PLoS One 9:e101041
Zhang, Weihe; DeRyckere, Deborah; Hunter, Debra et al. (2014) UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor. J Med Chem 57:7031-41

Showing the most recent 10 out of 292 publications